Utilizing BH3 profiling, a phase 2 study of Venetoclax monotherapy for R/R AML showed shorter durability of Venetoclax responses in patients with MCL-1 or BCL-xL dependence, suggesting that these mechanisms are operational in the clinical setting[4]. This evidence concerns the gene MCL1 and acute myeloid leukemia.